TYRA · Insider Trading
Tyra Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by TYRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Yuliya Rueb | Vice President, Finance (PAO) | A | +2,925 | +$26.70K |
| 2026-09-17 | Todd Harris | President and CEO | A | +864 | +$7.89K |
| 2026-09-17 | Alan Fuhrman | Chief Financial Officer | A | +951 | +$8.68K |
| 2026-09-17 | Rajeev M. Shah | Director | Buy | +45,392,645 deriv. | — |
| 2026-09-11 | Rehan Verjee | Director | Buy | +971 | +$20.00K |
| 2026-06-01 | Robert J More | Director | A | +13,160 deriv. | — |
| 2026-06-01 | Adele M. Gulfo | Director | A | +13,160 deriv. | — |
| 2026-06-01 | Rehan Verjee | Director | A | +13,160 deriv. | — |
| 2026-06-01 | Stephen Michael Rothenberg | Director | A | +13,160 deriv. | — |
| 2026-06-01 | Jake Simson | Director | A | +13,160 deriv. | — |
| 2026-06-01 | Susan Moran | Director | A | +13,160 deriv. | — |
| 2026-06-01 | RA Capital Nexus Fund, L.P. | Director | A | +65,800 deriv. | — |
| 2026-05-07 | Alan Fuhrman | Chief Financial Officer | A | +20,000 | — |
| 2026-05-07 | Bhavesh Ashar | Chief Operating Officer | A | +15,013 | — |
| 2026-05-07 | Yuliya Rueb | Vice President, Finance (PAO) | A | +8,333 | — |
| 2026-05-07 | Todd Harris | President and CEO | A | +79,000 | — |
| 2026-05-07 | Douglas J Warner | Chief Medical Officer | A | +25,000 | — |
| 2026-04-20 | Habib J Dable | Director | A | +44,400 deriv. | — |
| 2026-03-27 | Gilla Kaplan | Director | MIXED | −106,344 | −$2.62M |
| 2026-03-17 | Alan Fuhrman | Chief Financial Officer | A | +1,376 | +$12.56K |
| 2026-03-17 | Todd Harris | President and CEO | A | +1,463 | +$13.36K |
| 2026-02-13 | Daniel Bensen | Chief Discovery Officer | Sell | −8,000 | −$262.96K |
| 2026-01-20 | Daniel Bensen | Chief Discovery Officer | Sell | −8,000 | −$228.19K |
| 2025-12-19 | Robert J More | Director | Sell | −10,000 | −$250.00K |
| 2025-12-16 | Daniel Bensen | Chief Discovery Officer | Sell | −8,000 | −$181.16K |
| 2025-12-01 | Bhavesh Ashar | Chief Operating Officer | A | +300,000 deriv. | — |
| 2025-11-25 | Robert J More | Director | Sell | −246,871 | −$5.00M |
| 2025-11-19 | Daniel Bensen | Chief Operating Officer | Sell | −125,589 | −$2.03M |
| 2025-11-17 | Daniel Bensen | Chief Operating Officer | Sell | −131,411 | −$2.11M |
| 2025-09-17 | Alan Fuhrman | Chief Financial Officer | A | +701 | +$6.40K |
| 2025-08-07 | Douglas J Warner | Chief Medical Officer | A | +200,000 deriv. | — |
| 2025-08-07 | Daniel Bensen | Chief Operating Officer | A | +170,000 deriv. | — |
| 2025-08-07 | Todd Harris | President and CEO | A | +570,000 deriv. | — |
| 2025-08-07 | Alan Fuhrman | Chief Financial Officer | A | +170,000 deriv. | — |
| 2025-06-20 | Gilla Kaplan | Director | Sell | −9,578 | −$93.70K |
| 2025-06-16 | Gilla Kaplan | Director | Sell | −51,814 | −$534.56K |
| 2025-06-16 | Rajeev M. Shah | Director | Buy | +816,435 | +$8.32M |
| 2025-06-11 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | +934,250 | +$9.52M |
| 2025-06-06 | RA Capital Healthcare Fund LP | Director | Buy | +6,055,990 | +$58.76M |
| 2025-06-02 | Susan Moran | Director | A | +22,200 deriv. | — |
| 2025-06-02 | Jake Simson | Director | A | +22,200 deriv. | — |
| 2025-06-02 | Robert J More | Director | A | +22,200 deriv. | — |
| 2025-06-02 | Stephen Michael Rothenberg | Director | A | +22,200 deriv. | — |
| 2025-06-02 | Rehan Verjee | Director | A | +22,200 deriv. | — |
| 2025-06-02 | Gilla Kaplan | Director | A | +22,200 deriv. | — |
| 2025-06-02 | RA Capital Healthcare Fund LP | Director | A | +111,000 deriv. | — |
| 2025-03-18 | Todd Harris | President and CEO | A | +1,241 | +$12.13K |
| 2025-03-18 | Alan Fuhrman | Chief Financial Officer | A | +1,238 | +$12.10K |
| 2025-02-07 | Nina S Kjellson | Director | Sell | −5,401 | −$74.32K |
| 2025-01-31 | Adele M. Gulfo | Director | A | +37,200 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rajeev M. Shah | Director | 10,127,311 | $212.22M |
| RA Capital Healthcare Fund LP | Director | 9,695,820 | $203.18M |
| RA Capital Nexus Fund, L.P. | Director | 8,477,275 | $177.64M |
| Boxer Capital Management, LLC | — | 4,448,359 | $93.22M |
| Robert J More | Director | 3,823,425 | $80.12M |
| Todd Harris | President and CEO | 1,438,495 | $30.14M |
| Nina S Kjellson | Director | 443,885 | $9.30M |
| RA CAPITAL MANAGEMENT, L.P. | Director | 442,721 | $9.28M |
| Daniel Bensen | Chief Discovery Officer | 152,853 | $3.20M |
| Gilla Kaplan | Director | 42,526 | $891.13K |
| Alan Fuhrman | Chief Financial Officer | 37,115 | $777.74K |
| Douglas J Warner | Chief Medical Officer | 25,000 | $523.87K |
| Bhavesh Ashar | Chief Operating Officer | 15,013 | $314.60K |
| Yuliya Rueb | Vice President, Finance (PAO) | 11,258 | $235.91K |
| Rehan Verjee | Director | 971 | $20.37K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TYRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.